PLRX
Pliant Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.16
+2.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 1.6M | 9.7M |
| Cost of Revenue | 264.0K | 1.7M | — | — | — |
| Gross Profit | (264.0K) | (1.7M) | — | 1.6M | 9.7M |
| Operating Expenses | |||||
| R&D Expense | 63.6M | 109.2M | 169.3M | 127.8M | 96.9M |
| SG&A Expense | 33.3M | 47.2M | 59.1M | 57.9M | 39.9M |
| General & Admin Expense | 33.3M | 47.2M | 59.1M | 57.9M | 39.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 300.0K | (8.0M) | — | — | — |
| Total Operating Expenses | 97.2M | 148.4M | 228.4M | 185.7M | 136.9M |
| Cost and Expenses | 97.5M | 150.1M | 228.4M | 185.7M | 136.9M |
| Operating Income (EBIT) | (97.5M) | (150.1M) | (228.4M) | (184.1M) | (127.2M) |
| Non-Operating | |||||
| Interest Income | 6.5M | — | 21.1M | 24.1M | 4.7M |
| Interest Expense | 951.0K | 2.6M | 3.0M | 1.3M | 791.0K |
| Net Interest Income | 5.5M | (2.6M) | 18.1M | 22.8M | 3.9M |
| Other Non-Op Income/Expense | 5.2M | 729.0K | 18.1M | 22.8M | 3.9M |
| Non-Operating Income (excl Interest) | (8.1M) | (3.3M) | (21.1M) | (24.1M) | (4.7M) |
| EBT (Pre-Tax Income) | (92.3M) | (149.3M) | (210.3M) | (161.3M) | (123.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (92.3M) | (149.3M) | (210.3M) | (161.3M) | (123.3M) |
| Earnings from Cont. Ops | (92.3M) | (149.3M) | (210.3M) | (161.3M) | (123.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (92.3M) | (149.3M) | (210.3M) | (161.3M) | (123.3M) |
| Per Share | |||||
| Basic EPS | ($1.49) | ($2.43) | ($3.47) | ($2.75) | ($2.94) |
| Diluted EPS | ($1.49) | ($2.43) | ($3.47) | ($2.75) | ($2.94) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.03 | $0.23 |
| Shares | |||||
| Basic Shares Outstanding | 61.9M | 61.4M | 60.5M | 58.7M | 42.0M |
| Diluted Shares Outstanding | 61.9M | 61.4M | 60.5M | 58.7M | 42.0M |
| Profitability Metrics | |||||
| EBITDA | (88.1M) | (145.1M) | (205.2M) | (158.2M) | (118.8M) |
| D&A | 1.3M | 1.7M | 2.1M | 1.8M | 3.7M |
| EBIT | (89.4M) | (146.8M) | (207.3M) | (160.1M) | (122.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026